CTK is showing strong performance. The news that it launched an over-the-counter (OTC) cosmetics development service targeting the U.S. market appears to have had an impact.
As of 9:36 a.m. on the 24th, CTK was trading at 6,900 won, up 520 won (8.15%) from the previous trading day.
On the same day, CTK announced the launch of an OTC cosmetics development service aimed at the U.S. market.
OTC (Over The Counter drug) refers to general medicines that have proven safety and efficacy and can be used by the general public without a prescription. In the U.S., this category broadly includes sunscreen, acne care, skin protectants, dandruff care, and more, with demand particularly increasing. However, due to the stringent safety standards of the Food and Drug Administration (FDA), product development is complex and requires significant time and cost, making it a field that domestic brands and manufacturers have found difficult to enter.
CTK focused on this point and, based on extensive experience in planning and producing OTC products for U.S. beauty brands over a long period, launched an OTC service for domestic brands and manufacturers. The service uses safe and effective active ingredients that comply with all the strict standards set by the U.S. FDA. Products are manufactured by manufacturers with reliable OTC production facilities within the U.S.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
